Enable JavaScript to visit this website.

Dosing & Safety


To help protect them against MenB, ensure your teen completes all recommended doses of TRUMENBA

TRUMENBA follows a 2- or 3-dose schedule1

ACIP* recommends 2 doses for healthy teens2
Dose 1

at day 1

Dose 2

6 months after dose 1

ACIP* recommends 3 doses for persons who are at an increased risk of meningococcal disease or in a MenB outbreak situation2
Dose 1

at day 1

Dose 2

1-2 months after dose 1

Dose 3

6 months after dose 1

* The CDC Advisory Committee on Immunization Practices.

Discuss with your teen’s health care provider or pharmacist which schedule is appropriate for your teen

Complete the dose series

Your teen should receive all recommended doses of TRUMENBA to help protect them against MenB.

Watch the video to learn how easy it is to sign up for REMEMBER TRUMENBA.

Already received the first dose of TRUMENBA?
Get text reminders for the next dose.

Enroll now
helpful information

The safety data demonstrated that TRUMENBA was generally well tolerated.1

The safety of TRUMENBA was assessed in 11 clinical trials that included more than 15,000 adolescents and young adults.1

The most commonly reported side effects were pain at injection site, fatigue, headache, and muscle pain.1

When taken with other vaccines, local adverse reactions did not significantly increase.3,4

pharmacy icon

Want to know where you can get TRUMENBA near you?

Find a location
locator icon
Already received the first dose of TRUMENBA?

Get text reminders for the next dose.

Enroll now
  • Trumenba should not be given to anyone with a history of a severe allergic reaction after a previous dose of Trumenba
  • Some individuals with weakened immune systems may have a reduced immune response
  • Persons with certain complement deficiencies and persons receiving treatments such as Soliris® (eculizumab), are at increased risk for invasive disease caused by Neisseria meningitidis group B even with receipt of vaccination with Trumenba
  • As with any vaccine, vaccination with Trumenba may not protect all vaccine recipients against N meningitidis group B infections
  • Fainting can occur in association with administration of injectable vaccines, including Trumenba
  • The most common adverse reactions in adolescents and young adults were pain at injection site, fatigue, headache, and muscle pain. Nausea was reported in adolescents in early phase studies
  • Data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • Tell your health care provider if you are pregnant, or plan to become pregnant
  • Ask your health care provider about the risks and benefits of Trumenba. Only a health care provider can decide if Trumenba is right for you or your child
  • Trumenba is a vaccine indicated for individuals 10 through 25 years of age for active immunization to prevent invasive disease caused by Neisseria meningitidis group B
  • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis group B strains has not been confirmed
Call 1-844-TRUMENBA (878-6362), 9 AM to 7 PM ET, Monday through Friday, for more information.

Patients should always ask their doctors for medical advice about adverse events.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.

This product information provided in this site is intended only for residents of the United States. The products discussed in this site may have different product labeling in different countries.

The health information in this site is provided for educational purposes only and is not intended to replace discussions with a health care provider. All decisions regarding patient care must be made with a health care provider, considering the unique characteristics of the patient.

  1. TRUMENBA [package insert]. Philadelphia, PA: Pfizer Inc; 2019.
  2. Patton ME, Stephens D, Moore K, et al. Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine—Advisory Committee on Immunization Practices, 2016. MMWR Morb Mortal Wkly Rep. 2017;66(19):509-513.
  3. Senders S, Bhuyan P, Jiang Q, et al. Immunogenicity, tolerability and safety in adolescents of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with quadrivalent human papilloma virus vaccine. Pediatr Infect Dis J. 2016;35(5):548-554.
  4. Muse D, Christensen S, Bhuyan P, et al. A phase 2, randomized, active-controlled, observer-blinded study to assess the immunogenicity, tolerability and safety of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with tetanus, diphtheria and acellular pertussis vaccine and serogroup A, C, Y, and W-135 meningococcal conjugate vaccine in healthy US adolescents. Pediatr Infect Dis J. 2016;35(6):673-682.
Back to top